Eli Lilly has struck a deal to buy genetic-medicine biotechnology company Orna Therapeutics for up to $2.4 billion in cash.

NEW YORK – Eli Lilly on Monday said it will acquire in vivo CAR T-cell therapy developer Orna Therapeutics to strengthen its R&D work in genetic medicine and in vivo cell engineering.

Active Genetics (Pro-AG) exploits a naturally created bacterial mating tunnel between cells to inactivate antibiotic resistance.

Climate change is one of the principal driving forces intensifying abiotic stresses such as drought, salinity, flood and extreme heat and cold temperatures.

The field of regenerative medicine is entering an era of unprecedented convergence, bringing together intelligent biomaterials, biomedical hydrogels, and ...

Jeffrey Epstein corresponded with and funded numerous top scientists, with whom he shared his deranged ideas for improving ...

Antibiotic resistance (AR) has steadily accelerated in recent years to become a global health crisis. As deadly bacteria evolve new ways to elude drug treatments for a variety of illnesses, a growing ...

Combining genetic, structural, and digital innovations can provide an opportunity to develop climate-resilient cereals that ...

As a Ph.D. candidate in the Smith School of Chemical and Biomolecular Engineering, Nathan Piligian is developing a novel ...

Professor Jorge Riera discusses health care innovation and FIU’s role in South Florida’s growing biomedical ecosystem.

Over the past two decades, researchers have learned that DNA inside the cell nucleus naturally folds into a network of ...